Table 2.
Comparison of the estimated mean fold changes of different p-tau variants between different stages of Amyloid pathology in the post-mortem cohorts
| BLSA-Neuropathology cohort: amyloid pathology | ||||||
|---|---|---|---|---|---|---|
| Test - Plasma | Sparse versus Moderate | Sparse versus Frequent | Moderate versus Frequent | |||
| Result/analyte | Fold change | P-value | Fold change | P-value | Fold change | P-value |
| p-tau181 | 1.39 | 0.6703 | 1.69 | 0.2107 | 1.22 | 0.7231 |
| p-tau231 | 1.00 | 0.9999 | 1.70 | 0.0304 | 1.70 | 0.0271 |
| p-tau212 | 1.55 | 0.6339 | 2.70 | 0.0081 | 1.74 | 0.0867 |
| UCSD-Neuropathology cohort: CERAD amyloid pathology | ||||||
| –Test - CSF | Sparse versus Moderate | Sparse versus Frequent | Moderate versus Frequent | |||
| Result/analyte | Fold change | P-value | Fold change | P-value | Fold change | P-value |
| p-tau181 | 3.46 | 0.0114 | 4.21 | 0.0002 | 1.21 | 0.5582 |
| p-tau231 | 3.73 | 0.0122 | 4.57 | 0.0003 | 1.23 | 0.5536 |
| p-tau212 | 6.06 | 0.0083 | 8.72 | <0.0001 | 1.43 | 0.1589 |
| p-tau217 | 3.96 | 0.0034 | 5.27 | <0.0001 | 1.33 | 0.2053 |
| UCSD-Neuropathology cohort: Thal amyloid pathology | ||||||
| –Test - CSF | Thal 0-2 versus Thal 3-4 | Thal 0-2 versus Thal 5 | Thal 3-4 versus Thal 5 | |||
| Result/ analyte | Fold change | P-value | Fold change | P-value | Fold change | P-value |
| p-tau181 | 2.87 | 0.0799 | 3.47 | 0.0031 | 1.21 | 0.6684 |
| p-tau231 | 3.04 | 0.0781 | 3.62 | 0.0039 | 1.19 | 0.7355 |
| p-tau212 | 4.02 | 0.0921 | 5,73 | 0.0006 | 1.43 | 0.3162 |
| p-tau217 | 3.38 | 0.0403 | 4.55 | 0.0002 | 1.35 | 0.2930 |